Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61


Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats.

Lama A, Santoro A, Corrado B, Pirozzi C, Paciello O, Pagano TB, Russo S, Calignano A, Mattace Raso G, Meli R.

PLoS One. 2017 Feb 3;12(2):e0171276. doi: 10.1371/journal.pone.0171276.


Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation.

Osagie-Clouard L, Sanghani A, Coathup M, Briggs T, Bostrom M, Blunn G.

Bone Joint Res. 2017 Jan;6(1):14-21. doi: 10.1302/2046-3758.61.BJR-2016-0085.R1.


Using GWAS to identify novel therapeutic targets for osteoporosis.

Sabik OL, Farber CR.

Transl Res. 2017 Mar;181:15-26. doi: 10.1016/j.trsl.2016.10.009. Review.


Recombinant PTH associated with hypercalcaemia and renal failure.

Ayasreh N, Fernandez-Llama P, Lloret MJ, Da Silva I, BallarĂ­n J, Bover J.

Clin Kidney J. 2013 Feb;6(1):93-95. No abstract available.


PTH Induces Systemically Administered Mesenchymal Stem Cells to Migrate to and Regenerate Spine Injuries.

Sheyn D, Shapiro G, Tawackoli W, Jun DS, Koh Y, Kang KB, Su S, Da X, Ben-David S, Bez M, Yalon E, Antebi B, Avalos P, Stern T, Zelzer E, Schwarz EM, Gazit Z, Pelled G, Bae HW, Gazit D.

Mol Ther. 2016 Feb;24(2):318-30. doi: 10.1038/mt.2015.211. Erratum in: Mol Ther. 2016 Apr;24(4):843. Bae, Hyun M [Corrected to Bae, Hyun W].


Emerging Therapies for Osteoporosis.

McClung MR.

Endocrinol Metab (Seoul). 2015 Dec;30(4):429-35. doi: 10.3803/EnM.2015.30.4.429. Review.


Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE.

J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. Review. Erratum in: J Bone Miner Res. 2016 Oct;31(10 ):1910.


New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide.

Tanaka S, Adachi T, Kuroda T, Nakamura T, Shiraki M, Sugimoto T, Takeuchi Y, Saito M, Bilezikian JP.

Bone Res. 2014 Dec 23;2:14043. doi: 10.1038/boneres.2014.43.


Osteoporosis Treatment: When to Discontinue and When to Re-start.

Adami S, Idolazzi L, Fracassi E, Gatti D, Rossini M.

Bone Res. 2013 Dec 31;1(4):323-35. doi: 10.4248/BR201304003. Review.


Quantification of skeletal growth, modeling, and remodeling by in vivo micro computed tomography.

Altman AR, Tseng WJ, de Bakker CM, Chandra A, Lan S, Huh BK, Luo S, Leonard MB, Qin L, Liu XS.

Bone. 2015 Dec;81:370-9. doi: 10.1016/j.bone.2015.07.037.


Relevance of Wnt signaling for osteoanabolic therapy.

Yorgan TA, Schinke T.

Mol Cell Ther. 2014 Jul 14;2:22. doi: 10.1186/2052-8426-2-22. Review.


Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.

Chapurlat RD.

Ther Adv Musculoskelet Dis. 2015 Jun;7(3):103-9. doi: 10.1177/1759720X15580903. Review.


Three-times-weekly administration of teriparatide improves vertebral and peripheral bone density, microarchitecture, and mechanical properties without accelerating bone resorption in ovariectomized rats.

Takao-Kawabata R, Isogai Y, Takakura A, Shimazu Y, Sugimoto E, Nakazono O, Ikegaki I, Kuriyama H, Tanaka S, Oda H, Ishizuya T.

Calcif Tissue Int. 2015 Aug;97(2):156-68. doi: 10.1007/s00223-015-9998-0.


PTH(1-84) replacement therapy for the treatment of hypoparathyroidism.

Cusano NE, Rubin MR, Bilezikian JP.

Expert Rev Endocrinol Metab. 2015 Jan 1;10(1):5-13.


Denosumab for the treatment of osteoporosis.

Zaheer S, LeBoff M, Lewiecki EM.

Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):461-70. doi: 10.1517/17425255.2015.1000860. Review.


New strategies for osteoporosis patients previously managed with strontium ranelate.

Vestergaard P.

Ther Adv Musculoskelet Dis. 2014 Dec;6(6):217-25. doi: 10.1177/1759720X14552070. Review.


Safety of drugs used in the treatment of osteoporosis.

McGreevy C, Williams D.

Ther Adv Drug Saf. 2011 Aug;2(4):159-72. doi: 10.1177/2042098611411012. Review.


The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug.

de Waure C, Specchia ML, Cadeddu C, Capizzi S, Capri S, Di Pietro ML, Veneziano MA, Gualano MR, Kheiraoui F, La Torre G, Nicolotti N, Sferrazza A, Ricciardi W.

Biomed Res Int. 2014;2014:975927. doi: 10.1155/2014/975927.

Supplemental Content

Support Center